in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance.
.
�now we know the astonishing truth that some patients are waiting a year or more just to get treatment. it�s simply not good enough.�
.
subscribe today to be the first to to know about breaking news and special reports.
.
shuki sadeh
.
share on linkedin linkedin
.
the news highlighted another factor in the chinese threat: regardless of the different regulatory framework, many researchers think the data they report is valid.
.
. at this, shehbaz reassured them that the interview was taken out of context. this is unedited, unformatted feed from the press trust of india wire.